Fate and disposition of bromocriptine in animals and man. II: Absorption, elimination and metabolism
Tóm tắt
Từ khóa
Tài liệu tham khảo
Maurer, G., Schreier, E., Delaborde, S., Loosli, H.R., Nufer, R. and Shukla, A.P. (1982): Fate and disposition of bromocriptine in animals and man. I: Structure elucidation of the metabolites. Eur. J. Drug. Metab. Pharmacok.7, 281–292.
Meszaros, J., Nimmerfall, F., Rosenthaler, J., Weber, H. (1975): Permanent bile duct cannulation in the monkey. A model for studying intestinal absorption. Europ. J. Pharmacol.32, 233–242.
Bahr, C., Groth, C.G., Jansson, H., Lundgren, G., Lind, M., Glauman, H. (1980): Drug metabolism in human liver in vitro: establishment of a human liver bank. Clin. Pharmacol. Ther.27, 711–725.
Bradford, M. (1976): A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem.72, 248–254.
Eckert, H., Kiechel, J.R., Rosenthaler, J., Schmidt, R., Schreier, E. (1978): Biopharmaceutical aspects. Analytical methods, pharmacokinetics, metabolism and bioavailability. In: Berde, B., Schild, H.O. (eds): Ergot alkaloids and related compounds. Handbook Exp. Pharmacol.49, 719–803, Berlin, Heidelberg, New York: Springer.
Aellig, W.H., Nüesch, E. (1977): Comparative pharmacokinetic investigations with tritium labelled ergot alkaloids after oral and after intravenous administration in man. Int. J. clin. Pharmacol.15, 106–112.
Schran, H.F., Bhuta, S.I., Schwarz, H.J., Thorner, M.O. (1980): The pharmacokinetics of bromocriptine in man. In: Goldstein, M., Calne, D.B., Lieberman, A., Thorner, M.O. (eds): Ergot compounds and brain function: Neuroendocrine and neuropsychiatric aspects, pp. 125–139. New York: Raven Press.
Meier, J., Tanner, P., Sandoz Ltd. Basle, unpublished data.
Markey, S.P., Colburn, R.W., Kopin, I.J. Aamodt, R.L. (1979): Distribution and excretion in the rat and monkey of [82Br]bromocriptine. J. Pharmacol. Exp. Ther.211, 31–35.
Wong, S.H., Spencer, R.P., Hosain, P. (1978): Distribution and fate of 2-Br-82-alpha-ergokryptine and H-3-dihydroergokryptine in female rabbits. Fed. Proc.37, 741, Abstract No. 2773.
Giron-Forest, D.A., Schönleber, W.D. (1979): Bromocriptine methanesulphonate. An analytical profile. In: Florey, K. (ed.): Analytical profiles of drug substances. Vol.8, pp. 47–81. New York, London: Academic Press.
Larsen, N.E., Oehman, R., Larsson, M., Hvidberg, E.F. (1979): Determination of bromocriptine in plasma: Comparison of gas chromatography, mass fragmentography and liquid chromatography. J. Chromatography174, 341–349.
Price, P., Debono, A., Parkes, J.D., Mardsen, C.D., Rosenthaler, J. (1978): Plasma bromocriptine levels, clinical and growth hormone responses in parkinsonism. Brit. J. Clin. Pharmacol.6, 303–309.
Schran, H.F., Schwarz, H.J., Talbot, K.C., Loeffler, L.J. (1979): Specific analysis of ergot peptide alkaloids by radioimmunoassay. Clin. Chem.25, 1928–1933.
Fletcher, S., Vardi, J., Oberman, Z., Gilad, S., Allelov, M., Streifler, M. (1979): Plasma levels of bromocriptine after acute and chronic administration in parkinsonian patients: a radioimmunoassay study. Curr. Ther. Res.25, 540–543.
Thorner, M.O., Schran, H.F., Evans, W.S., Rogol, A.D., Morris, J.L., MacLeod, R.M. (1980): A broad spectrum of prolactin suppression by bromocriptine in hyperprolactinemic women. A study of serum prolactin and bromocriptine levels after acute and chronic administration of bromocriptine. J. Clin. Endocrinol. Metab.50, 1026–1033.
Nimmerfall, F., Rosenthaler, J. (1976): Ergot alkaloids: hepatic distribution and estimation of absorption by measurement of total radioactivity in bile and urine. J. Pharmacokinet. Biopharm.4, 57–66.
Friis, M.L., Gron, U., Larsen, N.E., Pakkenberg, H., Hvidberg, E.F. (1979): Pharmacokinetics of bromocriptine during continuous oral treatment of parkinson’s disease. Europ. J. Clin. Pharmacol.15, 275–280.